Skip to content

US · MASS · MEDICAL - SPECIALTIES

908 Devices Inc. (MASS) intrinsic value and stock valuation

$8.67as of 2026-11-21 · Mkt cap 345.04M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

908 Devices Inc. DCF and intrinsic value

InvestorsCraft values MASS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MASS’s statements →

908 Devices Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Specialties Burlington, MA 01803 908devices.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$56.2M+15.9% 5y CAGRd
20182025
Net income
-$-36.64M
20182025
Free cash flow
-$-24.64M
20182025
Total equity
$143.7M+0.7% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$56.2M$59.6M$50.2M$46.9M$42.2M
Operating income-$-24.18M-$-76.72M-$-42.76M-$-35.38M-$-22.07M
Net income-$-36.64M-$-72.21M-$-36.4M-$-33.56M-$-22.17M
EPSd-$-941.42K-$-2.12M-$-1.13M-$-1.07M-$-792.92K
Operating cash flow-$-23.69M-$-30.25M-$-25.06M-$-20.93M-$-29.08M
Capital expenditure-$-950K-$-600K-$-2.04M-$-2.04M-$-740K
Free cash flow-$-24.64M-$-30.85M-$-27.1M-$-22.98M-$-29.82M
Total assets$190.1M$159.5M$203M$242.6M$260.9M
Total debt$16.7M$6.61M$5.95M$19.5M$20.9M
Net debt-$-96.26M-$-37.42M-$-115.1M-$-168.91M-$-203.22M
Total equity$143.7M$114.6M$165.5M$190.6M$214.6M
Cash and short-term investments$113M$69.6M$145.7M$188.4M$224.1M
Income statement
20252024202320222021
Revenue$56.2M$59.6M$50.2M$46.9M$42.2M
Cost of revenue$29.4M$29.7M$24.9M$20.8M$19M
Gross profit$26.8M$29.9M$25.3M$26M$23.2M
Research and development expenses$13.8M$25.5M$21.9M$17.5M$13.1M
Selling, general and administrative expenses$37.2M$0.00$0.00$43.9M$32.2M
Other expenses$0.00$81.2M$46.2M$0.00$0.00
Operating expenses$51M$106.6M$68.1M$61.4M$45.3M
Cost and expenses$80.4M$136.4M$93M$82.2M$64.3M
Interest income$4.14M$4.49M$6.48M$2.03M$550K
Interest expense$0.00$0.00$200K$130K$490K
Depreciation and amortization$4.46M$4.68M$2.38M$1.61M$930K
Ebitda-$-28.88M-$-43.88M-$-40.27M-$-31.82M-$-20.76M
Operating income-$-24.18M-$-76.72M-$-42.76M-$-35.38M-$-22.07M
Total other income/expenses, net-$-9.16M$4.23M$6.15M$1.82M-$-100K
Income before tax-$-33.34M-$-72.49M-$-36.61M-$-33.56M-$-22.17M
Income tax expense-$-70K-$-280K-$-210K$0.00$0.00
Net income-$-36.64M-$-72.21M-$-36.4M-$-33.56M-$-22.17M
Weighted average shares outstanding$36.2M$34.1M$32.2M$31.5M$28M
Weighted average diluted shares outstanding$38.9M$34.1M$32.2M$31.5M$28M
Balance sheet
20252024202320222021
Cash and short-term investments$113M$69.6M$145.7M$188.4M$224.1M
Net receivables$11.3M$12.6M$8.99M$10M$16.6M
Inventory$13M$16.2M$14.9M$12.5M$7.92M
Total current assets$144.6M$103.1M$173.8M$215.6M$252.9M
Property, plant and equipment, net$8.63M$10.3M$9.57M$7.04M$6.79M
Goodwill and intangible assets$36.4M$45.3M$18.2M$18.5M$0.00
Long-term investments$0.00$0.00$170K$0.00$0.00
Total non-current assets$45.5M$56.4M$29.2M$27M$8.01M
Total assets$190.1M$159.5M$203M$242.6M$260.9M
Accounts payable$8.42M$2.06M$1.19M$1.4M$1.37M
Short-term debt$16.7M$1.86M$2.02M$1.47M$1.34M
Deferred revenue$8.93M$12.1M$10.6M$7.51M$5.16M
Total current liabilities$34.1M$25.2M$22.6M$19.2M$14.8M
Long-term debt$0.00$4.74M$3.93M$18M$19.5M
Deferred revenue, non-current$8.33M$10.7M$8.57M$11.5M$0.00
Total non-current liabilities$12.3M$19.7M$14.9M$32.8M$31.5M
Capital lease obligations$0.00$4.74M$3.93M$4.51M$5.85M
Total liabilities$46.4M$44.9M$37.5M$52M$46.3M
Common stock$40K$40K$30K$30K$30K
Retained earnings-$-223.32M-$-242.81M-$-170.6M-$-134.2M-$-100.64M
Accumulated other comprehensive income (loss)$50K$1.15M$1.36M$800K$0.00
Total equity$143.7M$114.6M$165.5M$190.6M$214.6M
Total investments$0.00$25.6M$24.8M$0.00$0.00
Total debt$16.7M$6.61M$5.95M$19.5M$20.9M
Net debt-$-96.26M-$-37.42M-$-115.1M-$-168.91M-$-203.22M
Cash flow statement
20252024202320222021
Net income$19.5M-$-72.21M-$-36.4M-$-33.56M-$-22.17M
Depreciation and amortization$3.83M$4.68M$2.38M$1.61M$930K
Stock-based compensation$9.85M$11.8M$9.79M$7.21M$2.5M
Change in working capital-$-15.3M-$-2.54M-$-1.57M$3.36M-$-12.44M
Accounts receivable$220K-$-2.93M$680K$5.93M-$-11.28M
Inventory-$-3.73M-$-1.66M-$-3.9M-$-5.47M-$-4.48M
Accounts payable-$-5.93M$0.00$0.00$0.00$2.75M
Net cash provided by operating activities-$-23.69M-$-30.25M-$-25.06M-$-20.93M-$-29.08M
Investments in property, plant and equipment-$-950K-$-600K-$-2.04M-$-2.04M-$-740K
Acquisitions, net-$-2M-$-44.78M$0.00-$-13.76M$0.00
Net cash used for investing activities$50.8M-$-46.32M-$-26.4M-$-15.81M-$-740K
Common stock issued$860K$1.15M$940K$1.55M$850K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-700K-$-380K-$-15.94M$1.18M$94.7M
Net change in cash$26.4M-$-77.01M-$-67.38M-$-35.54M$64.9M
Cash at end of period$70.6M$44.2M$121.2M$188.6M$224.1M
Operating cash flow-$-23.69M-$-30.25M-$-25.06M-$-20.93M-$-29.08M
Capital expenditure-$-950K-$-600K-$-2.04M-$-2.04M-$-740K
Free cash flow-$-24.64M-$-30.85M-$-27.1M-$-22.98M-$-29.82M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About 908 Devices Inc.

        908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.

        CEO
        Kevin J. Knopp
        Employees
        172
        Beta
        0.63

        Explore

        Frequently asked questions

        What is the intrinsic value of 908 Devices Inc. (MASS)?

        908 Devices Inc. (MASS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MASS undervalued?

        MASS trades at a price of $8.67 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.